ImmunityBio, Inc. vs Eli Lilly & Co.
IBRX vs LLY — side-by-side comparison from reported financials. IBRX leads 2, LLY leads 6 of 8 comparable metrics.
ImmunityBio, Inc.
IBRX · Healthcare
$10.57+6.66%Strained
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | IBRX | LLY |
|---|---|---|
| Price | $10.57 | $1 177.20 |
| Market cap | $11.2B | $1.05T |
| Revenue (TTM) | $166M | $79.7B |
| Revenue growth | +678.6% | +31.7% |
| Net margin | -598.6% | 33.5% |
| Free cash flow | -$288M | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +333.2% | +37.6% |
| P/E | — | 41.6 |
| P/E vs own history (cheap-side %) | — | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -193% | 93% |
| Altman Z-score | -6.14 | 7.10 |
| CV checks passed | 4 of 9 | 11 of 9 |
| Employees | 691 | 50,000 |
Full résumé-style profiles: IBRX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.